week 3 semaglutide side effects Your guide to GLP-1 Ozempic: Semaglutide is a GLP-1

Use In Specific Populations 8.1 Pregnancy Risk Summary There are limited data with semaglutide use in pregnant women to inform a drug-associated risk for adverse developmental outcomes

Discontinuation because of gastrointestinal symptoms is a real and measurable outcome in the trials

After discontinuation, close monitoring is essential: weight should be checked every 4-8 weeks initially, and for diabetes patients, self-monitoring of blood glucose or continuous glucose monitoring should continue as indicated, with A1C assessment within approximately 3 months of stopping to detect metabolic deterioration early and implement alternative management strategies

Women must have a negative pregnancy test before starting Qsymia and each month while taking the medication